NEZGLYAL

This brand name is authorized in Lithuania.

Active ingredients

The drug NEZGLYAL contains one active pharmaceutical ingredient (API):

1	Leriglitazone UNII WN9K42SAM6 - LERIGLITAZONE HYDROCHLORIDE
	Leriglitazone is a selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist. Leriglitazone decreases neuroinflammation through inhibition of NF-κB-mediated inflammatory signaling, protected neurons and astrocytes, and reduced microglia activation in in vitro models of cALD.
	Read more about Leriglitazone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NEZGLYAL Oral suspension	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AX23		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products
Discover more medicines within A16AX23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1108595